Literature DB >> 12955633

Pseudomonas aeruginosa bacteremia: risk factors for mortality and influence of delayed receipt of effective antimicrobial therapy on clinical outcome.

Cheol-In Kang1, Sung-Han Kim, Hong-Bin Kim, Sang-Won Park, Young-Ju Choe, Myoung-Don Oh, Eui-Chong Kim, Kang-Won Choe.   

Abstract

Among the nosocomial pathogens, Pseudomonas aeruginosa is recognized as a major cause of morbidity and mortality. Data on 136 patients with P. aeruginosa bacteremia were retrospectively analyzed to evaluate risk factors for mortality. The median age of the patients was 55 years (range, 15-85 years), 78.7% of the cases were hospital-acquired, and the 30-day mortality rate was 39% (53 of 136 patients). Multivariate analysis demonstrated that risk factors for mortality included severe sepsis, pneumonia, delay in starting effective antimicrobial therapy, and an increasing APACHE II score (all P values <.05). In 123 of the 136 patients (excluding 13 patients treated with inadequate definitive antibiotics), 30-day mortality was 27.7% (13 of 47 patients) in the group of patients who received initially effective empirical antimicrobial therapy, and 43.4% (33 of 76) in the group of patients who received delayed effective antimicrobial therapy (P=.079). There was a trend toward higher mortality as the length of delay increased. Delay in starting effective antimicrobial therapy for P. aeruginosa bacteremia tended to be associated with higher mortality.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12955633     DOI: 10.1086/377200

Source DB:  PubMed          Journal:  Clin Infect Dis        ISSN: 1058-4838            Impact factor:   9.079


  156 in total

1.  Resistance of gram-negative non-fermentative bacilli causing bloodstream infection, Vienna, 1996-2003.

Authors:  F Daxboeck; O Assadian; A Blacky; W Koller; A M Hirschl
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2004-04-27       Impact factor: 3.267

2.  Predictors of Mortality in Bloodstream Infections Caused by Pseudomonas aeruginosa and Impact of Antimicrobial Resistance and Bacterial Virulence.

Authors:  Raúl Recio; Mikel Mancheño; Esther Viedma; Jennifer Villa; María Ángeles Orellana; Jaime Lora-Tamayo; Fernando Chaves
Journal:  Antimicrob Agents Chemother       Date:  2020-01-27       Impact factor: 5.191

3.  Rapid and Consistent Evolution of Colistin Resistance in Extensively Drug-Resistant Pseudomonas aeruginosa during Morbidostat Culture.

Authors:  Bianca Dößelmann; Matthias Willmann; Matthias Steglich; Boyke Bunk; Ulrich Nübel; Silke Peter; Richard A Neher
Journal:  Antimicrob Agents Chemother       Date:  2017-08-24       Impact factor: 5.191

4.  Development and Assessment of Risk Scores for Carbapenem and Extensive β-Lactam Resistance Among Adult Hospitalized Patients With Pseudomonas aeruginosa Infection.

Authors:  Sara Y Tartof; Jennifer L Kuntz; Lie H Chen; Rong Wei; Laura Puzniak; Yun Tian; Theresa M Im; Harpreet S Takhar; Sanjay Merchant; Thomas Lodise
Journal:  JAMA Netw Open       Date:  2018-10-05

5.  Is fluoroquinolone monotherapy a useful alternative treatment for Pseudomonas aeruginosa bacteraemia?

Authors:  Ping-Feng Wu; Yi-Tsung Lin; Fu-Der Wang; Tsuey-Ching Yang; Chang-Phone Fung
Journal:  Infection       Date:  2018-03-20       Impact factor: 3.553

6.  Acute Inflammatory Response of Patients with Pseudomonas aeruginosa Infections: A Prospective Study.

Authors:  Silvia Gómez-Zorrilla; Francisco Morandeira; María José Castro; Fe Tubau; Elisabet Periche; Rosario Cañizares; María Angeles Dominguez; Javier Ariza; Carmen Peña
Journal:  Microb Drug Resist       Date:  2016-10-18       Impact factor: 3.431

7.  Population-based study of the epidemiology and the risk factors for Pseudomonas aeruginosa bloodstream infection.

Authors:  M D Parkins; D B Gregson; J D D Pitout; T Ross; K B Laupland
Journal:  Infection       Date:  2009-12-12       Impact factor: 3.553

8.  Controlling for severity of illness in outcome studies involving infectious diseases: impact of measurement at different time points.

Authors:  Kerri A Thom; Michelle D Shardell; Regina B Osih; Marin L Schweizer; Jon P Furuno; Eli N Perencevich; Jessina C McGregor; Anthony D Harris
Journal:  Infect Control Hosp Epidemiol       Date:  2008-11       Impact factor: 3.254

9.  A sensitive fluorescence-based assay for the detection of ExoU-mediated PLA(2) activity.

Authors:  Marc A Benson; Katherine M Schmalzer; Dara W Frank
Journal:  Clin Chim Acta       Date:  2009-11-10       Impact factor: 3.786

10.  Sporadic and outbreak cases of melioidosis in southern Taiwan: clinical features and antimicrobial susceptibility.

Authors:  H-I Shih; Y-C Chuang; B M-H Cheung; J-J Yan; C-M Chang; K Chang; N-Y Lee; H-C Lee; C-J Wu; P-L Chen; C-C Lee; L-R Wang; N-Y Ko; W-C Ko
Journal:  Infection       Date:  2008-10-14       Impact factor: 3.553

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.